Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …

Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

PURPOSE In SOLO1/GOG 3004 (ClinicalTrials. gov identifier: NCT01844986), maintenance
therapy with the poly (ADP-ribose) polymerase inhibitor olaparib provided a sustained …

PURPOSE ATHENA (ClinicalTrials. gov identifier: NCT03522246) was designed to evaluate
rucaparib first-line maintenance treatment in a broad patient population, including those …

Background Primary analyses of the phase III BrighTNess trial showed addition of
carboplatin with/without veliparib to neoadjuvant chemotherapy significantly improved …

Background Drug-induced interstitial lung disease (DIILD) is a form of interstitial lung
disease resulting from exposure to drugs causing inflammation and possibly interstitial …

Chemoresistance and metastasis are the major challenges for the current ovarian cancer
treatment. Understanding the mechanisms of ovarian cancer progression and metastasis is …

Over the past 15 years, rapid progress has been made in developmental therapeutics,
especially regarding the use of matched targeted therapies against specific oncogenic …

Ovarian cancer encompasses a heterogeneous group of malignancies that involve the
ovaries, fallopian tubes and the peritoneal cavity. Despite major advances made within the …

PARP inhibitors are the first clinically approved drugs that were developed based on
synthetic lethality. PARP inhibitors have shown promising outcomes since their clinical …